Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers
Metrics: PDF 891 views | HTML 1696 views | ?
Kedar Hastak1, Steven Bhutra2,3, Renate Parry4, James M. Ford1
1Department of Medicine, Division of Oncology, Stanford University, Stanford CA 94305, USA
2Department of Biology, Stanford University, Stanford CA 94305, USA
3Current address: Department of Medicine, Advocate Illinois Masonic Medical Center, Chicago, IL 60657, USA
4Varian Medical Systems, Palo Alto, CA 94306, USA
James M. Ford, email: email@example.com
Keywords: PARP inhibitor, fractionated radiation, combination therapy, radiosensitizer, lung cancer
Received: November 02, 2016 Accepted: February 06, 2017 Published: February 17, 2017
The development of stereotactic body radiation therapy (SBRT) has revolutionized radiation therapy for lung cancers and is an emerging treatment option for pancreatic cancers. However, there are many questions on how to optimize its use in chemoradiotherapy. The most relevant addition to radiotherapy regimens are inhibitors of DNA repair and DNA damage response pathways. One such class of agents are inhibitors of poly (ADP-ribose) polymerase (PARP). In this study we examined the effects of the PARP inhibitor LT626 in combination with ionizing radiation in lung and pancreatic cancers. Our study demonstrated that combination treatment with LT626 and radiation effectively inhibited growth in lung and pancreatic cancer cell lines, better than individual treatment alone. Combination treatment also increased expression of γH2AX and 53BP1 foci and upregulated expression of phosphorylated ATM, ATR and their respective kinases. Using in vivo lung cancer xenograft models we demonstrated that LT626 functioned as an effective radiosensitizer during fractionated radiation treatment, leading to significant decrease in tumor burden and doubling the median survival compared to control group. Overall our in vitro and in vivo studies showed that PARP inhibitor LT626 acted synergistically with radiation in lung and pancreatic cancers.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.